Drug reference
HIV infection in combination with other antiretroviral drugs when no suitable alternative available and when prescribed for shortest period possible ▶BY MOUTH ▶Adult (body-weight up to 60 kg): 30 mg every 12 hours, to be taken preferably at least 1 hour before food ▶Adult (body-weight 60 kg and above): 40 mg every 12 hours, to be taken preferably at least 1 hour before food
PDF page 713
Excessive alcohol intake. history of pancreatitis . history of peripheral neuropathy. lactic acidosis (especially when used in combination with didanosine)— use only if alternative regimens are not suitable CAUTIONS, FURTHER INFORMATION ▶Lactic acidosis Lactic acidosis associated with hepatomegaly and hepatic steatosis has been reported with stavudine. Use with caution in patients with hepatomegaly, hepatitis, or other risk factors for liver disease and hepatic steatosis (including obesity and alcohol abuse). Discontinue treatment if symptoms of hyperlactataemia, lactic acidosis, progressive hepatomegaly or rapid deterioration of liver function become apparent.
PDF page 713
Flavours of oral liquid formulations may include cherry. l LESS SUITABLE FOR PRESCRIBING Stavudine (especially in combination with didanosine) is associated with a higher Infection risk of lipoatrophy and should be used only if alternative regimens are not suitable; it is considered to be less suitable for prescribing.
PDF page 713
→Appendix 1: stavudine
PDF page 713
▶Common or very common Abnormal dreams. depression. drowsiness. dyspepsia. hyperlactacidaemia. lipoatrophy. nerve disorders. paraesthesia. peripheral neuropathy (switch to another antiretroviral if peripheral neuropathy develops). thinking abnormal ▶Uncommon Anxiety. appetite decreased. arthralgia. emotional lability. gynaecomastia. hepatic disorders. myalgia ▶Rare or very rare Diabetes mellitus. hyperglycaemia. muscle weakness. thrombocytopenia SIDE-EFFECTS, FURTHER INFORMATION Metabolic effects may occur with stavudine; plasma lipids and blood glucose concentrations should be measured routinely.
PDF page 713
Manufacturer advises use only if potential benefit outweighs risk.
PDF page 713
Risk of peripheral neuropathy. Dose adjustments Use half normal dose every 12 hours if eGFR 25–50 mL/minute/1.73 m2. Use half normal dose every 24 hours if eGFR less than 25 mL/minute/1.73 m2.
PDF page 713
No licensed medicines listed. eiiii F 683
PDF page 713
30 mg every 12 hours, to
First-line fragment. Read the complete Indications and Dose section above.
PDF page 713
40 mg every
First-line fragment. Read the complete Indications and Dose section above.
PDF page 713
